JAMA Neurol: Continuous immunotherapy in patients with secondary progressive multiple sclerosis reduces the risk of disability progression.

Recently, researchers examined the relationship between secondary multiple sclerosis (SPMS) treatment for disease modification therapy and disability accumulation.
the study was an observational cohort study, which collected data on 4,997 SPMS patients, of which 1,621 patients were fully followed up and included in the data analysis, examined the relationship between recurrence and disability accumulation rates in SPMS patients, and assessed whether treatment before or during the second progression period could alleviate the progress of disability accumulation.
the main endpoint of the study was the accumulation of disability in SPMS patients as a measure, and two results were analyzed: disability accumulation rate in the second progress ionphase phase and risk of wheelchair dependence. of the 1621 cases
1103 (68.0%) were female, the average age of MS was 33.9 years, and a total of 661 patients (40.8%) had relapses during SPMS.
for patients with recurrent remission multiple sclerosis, early treatment does not increase the cumulative risk of disability during relapse or secondary progression.
the high recurrence rate is associated with an increased risk of wheelchair dependence during the secondary disease phase (risk ratio: 1.87).
active access to disease modification therapy was significantly associated with reduced disability progression and reduced risk of wheelchair dependence in patients who experienced overlay recurrence during SPMS.
study found that active treatment for secondary multiple sclerosis could improve disability outcomes.
.